Aspirine et cancer colorectal : une promesse non tenue ?

Long-term aspirin therapy may be of preventive interest in the development of colorectal cancer (CRC), both in secondary prevention to avoid recurrence after resection, and in tertiary prevention to limit metastatic spread and consolidate response to treatment. However, long-term prescription of aspirin can be associated with adverse effects, including an increased risk of bleeding. Against this backdrop, international trials are currently underway to determine the efficacy of aspirin, particularly in adjuvant treatment in combination with chemotherapy after surgery. A few months ago, the initial results of the ASCOLT study reported at the European Oncology Congress (ESMO) were negative, with no argument for a favorable effect of aspirin intake after CRC surgery on specific mortality. However, sub-group analyses according to PIK3CA mutation have not yet been communicated. The question of the benefit of aspirin in CRC prevention therefore remains open. [ABSTRACT FROM AUTHOR]